
Join us for an in-depth exploration of the most impactful developments presented at the EULAR 2025 Congress, focusing specifically on Systemic Lupus Erythematosus and Lupus Nephritis.
We break down the key takeaways, including:
- New insights into hydroxychloroquine monitoring and glucocorticoid tapering guidance
- "LAMDA," a novel scoring system for lupus arthritis
- Breakthroughs in LN treatment, including the REGENCY trial for obinutuzumab and combinations with existing therapies.
- Updated perspectives on belimumab and anifrolumab, exciting novel therapies in development, and the future of cellular therapies for severe lupus.
Disclaimer: During Lupus Academy podcast episodes, participants may refer to off-label use of medicines for patients with lupus. Lupus Academy does not make anyrecommendations about using a medicine outside the terms of its approved license for use.
Weitere Episoden von „The Lupus Academy“
Verpasse keine Episode von “The Lupus Academy” und abonniere ihn in der kostenlosen GetPodcast App.